论文部分内容阅读
局部皮肤利什曼病(LCL)是由利什曼前鞭毛体侵入人体,并在巨噬细胞内寄生和繁殖所引起的一种疾病。有人曾报道,合用BCG 与墨西哥利什曼原虫对LCL 进行免疫治疗与用锑酸葡胺化学治疗具有相同的疗效,且无化学治疗所引起的副作用。本文介绍73例LCL 患者免疫、化学治疗前后细胞免疫各方面的变化情况。73例患者均选自LCL 流行区,经临床、
Topical cutaneous leishmaniasis (LCL) is a disease caused by Leishman’s promastigotes invade the body and parasitize and multiply in macrophages. It has been reported that immunotherapy of LCL with BCG and Leishmania mexico has the same effect as chemotherapy with meglumine antimonate without the side effects caused by chemotherapy. This article describes the 73 cases of LCL patients immunized, before and after chemotherapy in all aspects of cellular immunity changes. 73 patients were selected from the LCL epidemic area, the clinical,